Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14364458 | 0.88 | TAAR1 (0.49) | CA1CA2PDE3APDE4APDE4B | |
| SCHEMBL10053163 | 0.84 | CA1 (0.44) | CA1CA2PDE3APDE4APDE4B | |
| SCHEMBL10053153 | 0.83 | CA1 (0.47) | CA1CA2PDE3APDE4APDE4B | |
| SCHEMBL14342327 | 0.83 | CA1 (0.47) | CA1CA2PDE3APDE4APDE4B | |
| SCHEMBL10053182 | 0.82 | CA1 (0.61) | CA1CA2PDE3APDE4APDE4B | |
| SCHEMBL500198 | 0.81 | CA1 (0.59) | CA1CA2PDE3APDE4APDE4B | |
| SCHEMBL12589681 | 0.80 | CA1 (0.49) | CA1CA2PDE3APDE4APDE4B | |
| SCHEMBL10053161 | 0.80 | CA1 (0.49) | CA1CA2PDE3APDE4APDE4B | |
| SCHEMBL12589684 | 0.80 | CA1 (0.53) | CA1CA2PDE3APDE4APDE4B | |
| SCHEMBL10053166 | 0.80 | TAAR1 (0.49) | CA1CA2PDE3APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070286822-A1 | Compounds for the Treatment of Periodontal Disease | ANACOR PHARMACEUTICALS INC. (US) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070286822-A1 | Compounds for the Treatment of Periodontal Disease | BPGM, HMBS, PPIP5K2 | CA1 3204/4885CA2 1752/4885PDE3A 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.